NASDAQ:BTMD • US0906831039
BTMD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. BTMD has only an average score on both its financial health and profitability. BTMD scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROIC | 45.22% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Altman-Z | 2.2 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.37 | ||
| Fwd PE | 8.08 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.73 | ||
| EV/EBITDA | 5.94 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.06
+0.01 (+0.49%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.37 | ||
| Fwd PE | 8.08 | ||
| P/S | 0.48 | ||
| P/FCF | 2.73 | ||
| P/OCF | 2.35 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.94 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROCE | 57.24% | ||
| ROIC | 45.22% | ||
| ROICexc | 92.24% | ||
| ROICexgc | 190.38% | ||
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% | ||
| FCFM | 17.59% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Debt/EBITDA | 3.02 | ||
| Cap/Depr | 144.67% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 3.81 | ||
| Cash Conversion | 113.15% | ||
| Profit Quality | 119.51% | ||
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 2.2 |
ChartMill assigns a fundamental rating of 5 / 10 to BTMD.
ChartMill assigns a valuation rating of 9 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.
BIOTE CORP -A (BTMD) has a profitability rating of 6 / 10.
The financial health rating of BIOTE CORP -A (BTMD) is 4 / 10.
The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.